Aggreko


Dented by the Coronavirus and the oil crisis

24/03/20 -"We have trimmed our EPS estimates, factoring in the adverse impact of the Coronavirus pandemic on Aggreko’s revenue and supply-chain / COGS. Its event business is likely to suffer majorly in this ..."

Pages
43
Language
English
Published on
24/03/20
You may also be interested by these reports :
07/04/20
The higher-than-expected FY19 EPS was mainly attributable to the accounting restatements and corporate actions. However, in the wake of COVID-19 ...

07/04/20
While production at most of Bekaert’s Chinese plants has resumed (after pausing for a week on top of the holiday week for Chinese New Year), it has ...

06/04/20
In FY19, Elecnor recorded growth in both its revenue and profits. Although, the group deviated from its target of reducing exposure to its home ...

06/04/20
Although we have reduced our target price by 8% to €95, we remain positive on the stock and keep our Buy recommendation. Schneider has built a strong ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO